64th ASH Annual Meeting and Exposition: A clinical overview of REZLIDHIA (olutasidenib): A Newly Approved Therapy for the Treatment of Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation

-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member

denotes an abstract that is clinically relevant.

denotes that this is a recommended PHD Trainee Session.

denotes that this is a ticketed session.

A clinical overview of REZLIDHIA (olutasidenib): A Newly Approved Therapy for the Treatment of Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation

Sponsor: Rigel Pharmaceuticals

Product Theaters

Hall J - Theater 4 (Ernest N. Morial Convention Center)

Speaker:

Aaron Sheppard, PhD, Rigel Pharmaceuticals

Disclosures:

No relevant conflicts of interest to declare.

For in-person participants only

See more of: Product Theaters